Rubin Lab

DE-ESCALATION OF IBD TREATMENT

De-escalation of IBD treatment is an important topic, not only because patients frequently ask when they can stop their therapies, but also in consideration of the costs of therapies, long-term exposures of therapies, and in the chronic management of a condition like Crohn’s disease or ulcerative colitis.

Click here to listen to more about why, when, and how to de-escalate.

POSITIONING THERAPIES FOR IBD

With the vast options for IBD therapies in our modern world, which therapy is the right choice? Therapies are individual and dependent on multiple dimensions of disease control, need to be monitored, and optimized.

Click here to listen to the recording of this virtual grand rounds.

CANCER PREVENTION IN IBD

Prevention, monitoring, and treatment strategies for not only colorectal cancer in IBD, but also skin cancer, lymphoma, cervical cancer, and anal cancer.

HIGH RISK ULCERATIVE COLITIS: WHERE DO WE START?

Presented at the American College of Gastroenterology 2019 conference. David T. Rubin, MD discusses treatment options for patients with high risk ulcerative colitis.

YEAR IN REVIEW: CROHN’S DISEASE IN 2019

Presented in 2019 at the GUILD. David T. Rubin, MD gives an overview of Crohn’s disease treatment.